Studio Pilota RCT LiveWell mBC
LiveWell mBC: Test Pilota di un Programma di Formazione alle Competenze della Terapia Dialettico-Comportamentale Adattato per Gruppi di Donne Affette da Carcinoma Mammario Metastatico
In this pilot randomized controlled trial, women with metastatic breast cancer and at least mild distress (N=48) will be randomized to receive LiveWell mBC, a group-based adapted Dialectical Behavioral Therapy (DBT) Skills Training protocol, or Usual Care. The investigators will evaluate feasibility, acceptability, and preliminary efficacy of LiveWell to reduce distress (primary outcome) and improve psychological well-being, symptom burden, and quality of life (secondary outcomes).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Participants will be randomized 2:1 to receive LiveWell mBC, an adapted DBT Skills Training intervention delivered to small groups of women with mBC via telehealth, or usual care. LiveWell mBC involves orientation + an 8-session skills training protocol of mindfulness, emotion regulation, distress tolerance and interpersonal effectiveness.
Participants will complete self-report measures at baseline, mid-intervention (Week 5), post-intervention (Week 11) and 1 month post-intervention (Week 15). It is hypothesized that: 1) RCT methods will demonstrate evidence of feasibility (>70% overall retention rate, >70% LiveWell mBC completion rate); 2) RCT methods will demonstrated evidence of acceptability (>50% enrollment rate, >80% participant satisfaction); and 3) LiveWell participants will demonstrate reductions in distress (primary outcome) compared to Usual Care at 11-week follow-up.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Kathryn Moody
- Numero di telefono: 843-792-9698
- Email: moodykat@musc.edu
Backup dei contatti dello studio
- Nome: Benjamin Axelrod
- Numero di telefono: 843-876-2645
- Email: axelrod@musc.edu
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- identify as female
- be diagnosed with metastatic (AJCC stage IV) breast cancer
- be receiving care for metastatic breast cancer at Hollings Cancer Center
- endorse >3 out of 10 on the NCCN distress thermometer over the past week plus at least one emotional concern on the problem checklist
- be > 18 years of age
- be able to understand, speak, and read English
- be able to provide informed consent.
Exclusion Criteria:
- reported or suspected cognitive impairment
- presence of untreated serious mental illness (e.g., schizophrenia) indicated by the medical chart or treating oncologist
- expected survival <6 months, as indicated by a hospice referral
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Nessun intervento: Usual Care
Will receive a handout with general support resources available at Hollings Cancer Center. |
|
|
Sperimentale: LiveWell mBC: A Group-Based Adapted Dialectical Behavioral Therapy Skills Training Program
Will receive 9 telehealth-delivered small group (6-8 participants) sessions (orientation + 8 session DBT skills training protocol) co-facilitated by two skills trainers. Sessions will be 90 minutes each and delivered approximately weekly. Sessions will teach skills from dialectical behavioral therapy (e.g., mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness) adapted for patients with metastatic breast cancer. Sessions follow a standardized structure, including 1) mindfulness practice, 2) home practice and diary card review, 3) learning and practicing new skills, and 4) closing ritual. Participants will have access to a resource library of skills training videos and mindfulness recordings. |
LiveWell mBC: A Group-Based Adapted Dialectical Behavioral Therapy Skills Training Program |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
PROMIS Depression Short Form (8a)
Lasso di tempo: Baseline (week 0), post-intervention (week 11), and 1-month follow-up (week 15)
|
Depression will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression (8 items) Short Form Scale. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater depressive symptomology. |
Baseline (week 0), post-intervention (week 11), and 1-month follow-up (week 15)
|
|
PROMIS Anxiety Short Form (7a)
Lasso di tempo: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
Anxiety will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety (7 items) Short Form Scale. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater anxiety symptomology. |
Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Intolerance of Uncertainty Scale - Short Form (IUS-12)
Lasso di tempo: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
The 12-item Intolerance of Uncertainty Scale (IUS) Short Form will be used to measure emotional, cognitive, and behavioral reactions to uncertain situations. The IUS has a score range of 12-60, where a higher score indicates greater intolerance of uncertainty. |
Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
|
Peace, Equanimity, and Acceptance in the Cancer (PEACE) - Peaceful Acceptance of Illness Subscale
Lasso di tempo: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
The 5-item Peace, Equanimity, and Acceptance in the Cancer (PEACE) - Peaceful Acceptance of Illness Subscale will be used to assess patient-reported acceptance, inner peace, and tranquility in the context of cancer. The subscale has a score range of 5-20, where a higher score indicates greater peaceful acceptance of illness. |
Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
|
PROMIS Positive Affect Short Form (15a)
Lasso di tempo: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
The PROMIS Positive Affect Short Form 15a will be used to assess patient-reported positive emotions and well-being over the past 7 days. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater positive affect. |
Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
|
Difficulty in Regulating Emotions Scale (DERS-18)
Lasso di tempo: Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
|
The DERS-18 will be used to assess emotion dysregulation. The DERS-18 has a score range of 18-80, where a higher score indicates greater difficulty with regulating emotions. |
Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
|
|
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Lasso di tempo: Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
|
The 10-item Cognitive and Affective Mindfulness Scale-Revised will be used to assess patient-reported mindfulness qualities, including present-moment awareness, acceptance, and attention. The CAMS-R has a score range of 10-40, where a higher score indicates greater mindfulness. |
Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
|
|
DBT Ways of Coping Checklist (DBT-WCCL) - DBT Skills Subscale (DSS)
Lasso di tempo: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
The DBT Ways of Coping Checklist (DBT-WCCL) -DBT Skills Subscale (DSS) will be used to assess patient-reported frequency of skill use to manage difficult situations. The DBT-WCCL has a score range of 0 to 4, where a higher score indicates greater DBT skill use. |
Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
|
NCI Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE)
Lasso di tempo: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
The NCI-PRO-CTCAE will be used to assess patient-reported symptom frequency, severity, and interference related to breast cancer and its treatment. Items are rated on a 5-point Likert scale, with higher scores indicating greater symptom burden. |
Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
|
PROMIS Self-Efficacy for Managing Emotions Short Form (8a)
Lasso di tempo: Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
|
The PROMIS Self-Efficacy for Managing Emotions 8-item Short Form will be used to assess patient-reported confidence in managing negative emotions and emotional distress related to chronic illness. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater self-efficacy for managing emotions. |
Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
|
|
PROMIS Self-Efficacy for Managing Symptoms Short Form (8a)
Lasso di tempo: Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
|
The PROMIS Self-Efficacy for Managing Symptoms 8-item Short Form will be used to assess patient-reported confidence in managing symptoms and limiting their interference with daily life. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater self-efficacy for managing symptoms. |
Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
|
|
Functional Assessment of Cancer Therapy - Breast (FACT-B)
Lasso di tempo: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
The FACT-B will be used to assess patient-reported quality of life across physical, social/family, emotional, and functional domains, as well as breast cancer-specific concerns. Items are rated on a 5-point Likert scale (0 = Not at all to 4 = Very much) and summed to form subscale and total scores. Higher subscale and total scores indicate better quality of life. |
Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
|
PROMIS Emotional Support
Lasso di tempo: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
The PROMIS Emotional Support (4a) Short Form will assess social support. The PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater access to social support networks. |
Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
|
|
Group Therapy Experience Scale
Lasso di tempo: Post-intervention (week 11)
|
The Group Therapy Experience Scale will measure perceived cohesion, self-disclosure, and satisfaction with group therapy. The 16 item scale uses a Likert scale with responses ranging from 1(strongly disagree) to 5(strongly agree). Higher scores indicate higher satisfaction with group therapy. |
Post-intervention (week 11)
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Kelly Hyland, PhD, Medical University of South Carolina
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- Pro00149650
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .